Loading
Newron Pharmaceuticals S.p.A. Stock: price and insider trades · Switzerland
2 insiders bought €125k of shares over the last 90 days, the latest filed 08 Oct 2026.
Cluster: 2 buyers in 30 daysNewron Pharmaceuticals S.p.A.: what insiders have been doing
Newron Pharmaceuticals S.p.A., classified in the Health Care sector, is a listed company based in Bresso, Italy, founded in 1999. Its insiders report their share dealings to SIX SER. Between 18 October 2025 and 18 October 2026, 3 insiders published 8 filings.
Both sides are active: 6 purchases worth €125k and 2 sales worth €377k, from 2 insiders and 1 insider respectively. Taken together, the sales exceed the purchases by €252k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 2 senior executives. At €265k, the sale published on 26 November 2025 is the largest of the period.
Compared with its exchange (177 companies, median 9 filings), a count of 8 filings is below the norm. Since 2024, the database holds 12 purchases and 3 sales by insiders of the company.
In the case of 4 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The latest purchase is recent: it was published 9 days ago, on 8 October 2026. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from SIX SER. Past trades are no guide to future returns.
Key facts
Headquarters: Bresso, Italy · Founded: 1999
Source: Wikidata (CC0).
Insider Decl.
15
Thresholds
n/a
Buy Volume
€289,888
12 ops. · all time
Sell Volume
€487,256
3 ops. · all time
Who traded when
BuySaleAnonymous (Executive member of the board of directors / member of senior management)4 buys
Anonymous (an executive member of the board of directors / member of senior management)3 buys
Anonymous (Non-executive member of the board of directors)1 buy2 sales
Since the insiders bought
- Anonymous (an executive member of the board of directors / member of senior management)-11.0%Entry CHF 12.42 · Close at T+30 CHF 11.06
- Anonymous (Executive member of the board of directors / member of senior management)-14.5%Entry CHF 12.94 · Close at T+30 CHF 11.06
- Anonymous (Non-executive member of the board of directors)+117.0%Entry CHF 7.18 · Close at T+365 CHF 15.58
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Newron Pharmaceuticals S.p.A. Strong Buy (bullish), based on 4 analysts. Average price target: CHF 38.27.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
CHF 7.97
Analyst consensus
4 analystsStrong buy
CHF 18.97Target CHF 38.27(+380%)CHF 72.89
Income statement
RevenueCHF 19.1M
EBITDA-CHF 7.8M-41% margin
Net income-CHF 13.2M-283.6% margin
Valuation
PER (forward)13.5x
Beta0.85
Balance sheet & cash
Market capCHF 163M
Total debtCHF 38.2M
Free Cash FlowCHF 32.3M
Profitability & ownership
ROA-27.8%
% insiders12.8%
% institutions12.5%
Last declaration on 8 October 2026
Declarations15 total
▲
Anonymous (an executive member of the board of directors / member of senior management)
1,500 shares@ CHF 7.190.0071% mcap18.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1QA800017
Canonical exit: 6 Jan 2027 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,500 shares@ CHF 7.18710.0071% mcap9.7% of flowISIN IT0004147952SIX:T1QA800017
Canonical exit: 6 Jan 2027 (T+90)
▲
Anonymous (an executive member of the board of directors / member of senior management)
2,000 shares@ CHF 11.810.011% mcap49.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8C00022
Canonical exit: 10 Nov 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,000 shares@ CHF 11.80630.011% mcap23.5% of flowISIN IT0004147952SIX:T1Q8C00022
Canonical exit: 10 Nov 2026 (T+90)
▲
Anonymous (an executive member of the board of directors / member of senior management)
2,000 shares@ CHF 11.980.011% mcap50.4% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8B00016
Canonical exit: 9 Nov 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,000 shares@ CHF 11.9810.011% mcap23.9% of flowISIN IT0004147952SIX:T1Q8B00016
Canonical exit: 9 Nov 2026 (T+90)
5,465 shares@ CHF 19.0718.7% of flowISIN IT0004147952SIX:T1PC200035
14,567 shares@ CHF 17.023744.5% of flowSIX:T1PBQ00061
750 shares@ CHF 7.2961.0% of flowISIN IT0004147952SIX:T1P4N000A0
Canonical exit: 22 Jul 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
5,000 shares@ CHF 6.465132.2% of flowISIN IT0004147952SIX:T1P4700052
Canonical exit: 6 Jul 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 8.423120.4% of flowISIN IT0004147952SIX:T1O6R00018
Canonical exit: 25 Sept 2024 (T+90)
2,502 shares@ CHF 9.78074.3% of flowISIN IT0004147952SIX:T1O6P00046
Canonical exit: 23 Sept 2024 (T+90)
5,498 shares@ CHF 9.7619.4% of flowISIN IT0004147952SIX:T1O6H00035
Canonical exit: 15 Sept 2024 (T+90)
2,000 shares@ CHF 10.223.6% of flowISIN IT0004147952SIX:T1O6E00057
Canonical exit: 12 Sept 2024 (T+90)
10,382 shares@ CHF 10.467818.5% of flowISIN IT0004147952SIX:T1O5G000E3
15 of 15 declarations
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing treatments for central nervous system diseases. It is listed on the Swiss Stock Exchange (XSWX).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
